Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MEK Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT06104488
What this trial is testing

Avutometinib for People With Solid Tumor Cancers

Who this might be right for
Refractory CancerCNS TumorsCNS Tumor, Adult+12 more
Memorial Sloan Kettering Cancer Center 3
Testing effectiveness (Phase 2)Ended earlyNCT04488003
What this trial is testing

Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

Who this might be right for
Advanced Solid TumorBRAF Gene MutationBRAF Gene Alteration+6 more
BioMed Valley Discoveries, Inc 104
Testing effectiveness (Phase 2)Study completedNCT02834364
What this trial is testing

BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)

Who this might be right for
Relapsed or Refractory Multiple MyelomaPatients With BRAFV600 E or BRAFV600K Mutation
University of Heidelberg Medical Center 12
Post-approval studies (Phase 4)WithdrawnNCT07092410
What this trial is testing

Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib

Who this might be right for
Melanoma BRAF V600E/K Mutated
SRH Wald-Klinikum Gera GmbH
Early research (Phase 1)Ended earlyNCT07121829
What this trial is testing

Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

Who this might be right for
MelanomaSolid TumorPilocytic Astrocytoma+7 more
Day One Biopharmaceuticals, Inc. 44
Testing effectiveness (Phase 2)Study completedNCT01726738
What this trial is testing

LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations

Who this might be right for
Stage III MelanomaStage IV MelanomaUnresectable Melanoma+1 more
UNC Lineberger Comprehensive Cancer Center 17
Testing effectiveness (Phase 2)Study completedNCT01750918
What this trial is testing

BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)

Who this might be right for
Cancer
Novartis Pharmaceuticals 166
Testing effectiveness (Phase 2)Study completedNCT03244956
What this trial is testing

Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer

Who this might be right for
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
Gustave Roussy, Cancer Campus, Grand Paris 40
Testing effectiveness (Phase 2)Ended earlyNCT01085331
What this trial is testing

MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)

Who this might be right for
Metastatic Colorectal Cancer
EMD Serono 16
Testing effectiveness (Phase 2)Study completedNCT01333475
What this trial is testing

MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma

Who this might be right for
Colorectal Neoplasms
National Cancer Institute (NCI) 21
Not applicableAvailableNCT04566393
What this trial is testing

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Who this might be right for
Pancreatic CancerSmall Bowel CancerColorectal Cancer+18 more
xCures
Testing effectiveness (Phase 2)WithdrawnNCT01328106
What this trial is testing

Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma

Who this might be right for
GNA11 Mutation-positive Metastatic MelanomaGNAQ Mutation-positive Metastatic MelanomaCancer+1 more
GlaxoSmithKline
Testing effectiveness (Phase 2)Study completedNCT02124772
What this trial is testing

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

Who this might be right for
Cancer
Novartis Pharmaceuticals 139
Early research (Phase 1)Study completedNCT03434262
What this trial is testing

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Who this might be right for
Anaplastic AstrocytomaAnaplastic EpendymomaAnaplastic Ganglioglioma+53 more
St. Jude Children's Research Hospital 68
Testing effectiveness (Phase 2)Active Not RecruitingNCT04557956
What this trial is testing

Testing the Addition of the Anti-cancer Drug, Tazemetostat, to (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

Who this might be right for
Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Melanoma
National Cancer Institute (NCI) 16
Testing effectiveness (Phase 2)WithdrawnNCT03972046
What this trial is testing

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

Who this might be right for
Melanoma (Skin)Melanoma Stage IIIb-IVM1aMetastasis Skin+2 more
TriHealth Inc.
Early research (Phase 1)Study completedNCT01767454
What this trial is testing

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

Who this might be right for
Solid Tumours
GlaxoSmithKline 38
Testing effectiveness (Phase 2)Ended earlyNCT03430947
What this trial is testing

Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases

Who this might be right for
Malignant Melanoma Stage IVBRAF V600 MutationBrain Metastases
Technische Universität Dresden 20
Not applicableUnknownNCT05510466
What this trial is testing

Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis

Who this might be right for
Metastatic Melanoma
University Hospital, Montpellier 18
Testing effectiveness (Phase 2)Looking for participantsNCT06229340
What this trial is testing

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations

Who this might be right for
RAS MutationRas (Kras or Nras) Gene MutationColorectal Cancer Recurrent+4 more
N.N. Petrov National Medical Research Center of Oncology 20
Next Page